Business Wire

c-LEcta Continues Its Growth in 2020 and Increases Its EBITDA Above Average

15.12.2020 11:40:00 EET | Business Wire | Press release

Share

c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its growth in 2020 in what turned out to be a challenging year overall. Besides increasing its sales to more than EUR 10 million, an EBITDA margin in the double-digit percentage range is already expected this year. Management also expects increases in sales and the EBITDA margin in 2021. This is due to well-filled order books and high-growth products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005477/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

An employee of c-LEcta operates a system for the production of enzymes. Through the strategic approach of a product company c-LEcta positions itself for future growth. Photo: c-LEcta / Eric-Kemnitz.com (Photo: Business Wire)

The Leipzig-based company can look back on a successful 2020 and is planning for a stronger future. c-LEcta’s broad-based business model has proven its value. Growth pauses for individual products during the pandemic year were offset by strong performances in other areas. Positive impetus came from the pharmaceuticals business in particular. The product company’s strategy thus continues to bear fruit. Over 85 % of sales now come from products. Sales will ultimately exceed the psychologically important EUR 10 million mark for 2020.

At the same time, c-LEcta is also demonstrating its earnings potential: the changed product mix will result in a double-digit EBITDA margin earlier than expected in 2020. c-LEcta also broadened its reach geographically this year, putting it in a strong position to take advantage of opportunities around the world. In total, the company shipped its products to more than 25 countries on three continents with sales in the United States developing above average.

The order book is already well filled for next year. Based on this, c-LEcta expects sales to develop disproportionately strongly. Despite the strategic focus on the company’s growth, a significant improvement in the EBITDA margin is also planned again.

“This year, we have shown that our growth is based on a solid foundation that has maintained and even strengthened in 2020,” commented Thomas Pfaadt, CFO of c-LEcta. “With our very good EBITDA, we are also showing that we can be profitable. We will achieve a clearly positive EBITDA margin earlier than planned, which of course also strengthens us for investment in further growth opportunities. Therefore, we will continue to systematically implement our successful strategy.”

A product called DENARASE, which is used in gene and cell therapy, but is also required for production of certain types of vaccines, was the biggest driver of growth in 2020. Therefore, significant momentum came from vaccine development and production in 2020. In the medium term, however, c-LEcta’s management expects demand to develop dynamically, especially from gene and cell therapy. Market researchers expect the global market for gene and cell therapy to grow at a CAGR of over 25% through 2027.1

The DENARASE ELISA kit was also launched in 2020 to complement the company’s current products. The kit can be used to detect DENARASE residues. Thus, c-LEcta is supplementing its portfolio surrounding DENARASE, also from a technological point of view. The new product was received very positively and already exceeded expectations in terms of sales and performance in customer applications in the year of the sales launch.

“We are very pleased with the success of our product DENARASE, with which we are also making our contribution to the fight against the pandemic,” commented Dr. Marc Struhalla, founder and CEO of c-LEcta. “At the same time, we expect continued strong development with this product, not only in vaccine manufacturing, but especially from the field of gene and cell therapy. This is a major topic for the future. In the medium term, we also expect continued impetus from the food industry and from new products in our pipeline.”

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 90 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

1 Allied Market Research, September 2020

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

cometis AG
Matthias Kunz
Phone: +49 (0) 611 - 205855 – 64
Fax: +49 (0) 611 - 205855 – 66
email: kunz@cometis.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization18.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced an expanded strategic partnership with American Digital Corporation to give SAP licensees a lower-risk, more flexible path to cloud modernization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118330258/en/ Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization Through the expanded relationship, American Digital will serve as a solution partner for Rimini Cloud™ for SAP, helping SAP ECC and S/4HANA licensees move their existing SAP systems to modern cloud infrastructure without requiring ERP reimplementation or conversion of perpetual licenses to subscriptions, while maintaining greater control over their long-term roadmap. The announcement builds on a strategic alliance establish

Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 16:00:00 EET | Press release

Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118877583/en/ Sila, a leading battery technology and materials company, today announced a comm

Two Cessna SkyCourier Aircraft Enter Aero-Medical Service With Delivery to Tassili Travail Aérien18.11.2026 16:00:00 EET | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced it has delivered two Cessna SkyCourier aircraft equipped for aero-medical missions to Tassili Travail Aérien (TTA) of Algeria. The aircraft are the first aero-medical SkyCouriers in Africa and the first customer SkyCouriers to enter service on the continent, expanding the aircraft’s global presence and demonstrating its versatility for critical special missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015092210/en/ Textron Aviation completes delivery of Africa’s first two aero-medical equipped Cessna SkyCourier aircraft to Tassili Travail Aérien, also marking the first SkyCourier deliveries in Africa, expanding the aircraft’s special-mission capabilities. The two aircraft will support TTA’s passenger transportation and aero-medical evacuation operations serving Algeria’s energy sector. Equipped with the LifePort PLUS Powered Medevac System,

KŌZĒ Stays Launches International Expansion with More Than 1,200 Properties18.11.2026 15:28:00 EET | Press release

KŌZĒ Stays announces a major international expansion, bringing its curated portfolio to more than 1,200 properties worldwide. Following eight consecutive years of rapid growth, the company is building on its established presence in Mont-Tremblant and the Laurentians to pursue a broader ambition in international hospitality. The expanded collection spans French and Swiss alpine chalets, Riviera villas near Monaco, Lake Como residences, private retreats in St. Barths and homes on Dubai’s Palm Jumeirah. Available through The KŌZĒ Collection, these properties extend the brand’s reach into some of the world’s most sought-after destinations. Canadian Roots, International Ambition “A guest who loves their stay with us in Mont-Tremblant should be able to book their next trip, whether that’s Verbier, St. Barths or Lake Como, knowing the KŌZĒ standard travels with them,” said Jeffery Khoury, Founder and CEO of KŌZĒ Stays. “That’s what this expansion is about: one name you trust, wherever you tra

Blue Yonder Announces New Leadership18.11.2026 15:03:00 EET | Press release

Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believe there is a significant additional opportunity to build on that solid foundation to expand the company’s software platform to help

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye